The relationship between borderline ovarian tumors and epithelial ovarian carcinoma: Epidemiologic, pathologic, and molecular aspects

Gynecologic Oncology

Volumn 60, Issue 3, 1996, Pages 347-354

  Link Jr , Charles J ^a   Kohn, Elise ^b   Reed, Eddie ^b  

^a Iowa Cancer Research Foundation   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CLOMIFENE; GAMMA GLUTAMYLTRANSFERASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ANEUPLOIDY; CARCINOGENESIS; CLINICAL ARTICLE; DNA CONTENT; FEMALE; GENE MUTATION; GENETIC MARKER; HUMAN; HUMAN TISSUE; MOLECULAR BIOLOGY; ONCOGENE K RAS; ONCOGENE NEU; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REVIEW;

EID: 0029932101     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0054     Document Type: Review

References (64)

1. Leake, J. F. Tumors of low malignant potential, Curr. Opin. Obstet. Gynecol. 4, 81-85 (1992).
2. Nation, J. G., and Krepart, G. V. Ovarian carcinoma of low malignant potential: Staging and treatment, Am. J. Obstet. Gynecol. 154, 290-293 (1986).
3. Young, R. C., Perez, C. A., and Hoskins, W. J. Cancer of the ovary, in Cancer principles and Practice of Oncology (V. T. DeVita Jr., S. Hellman, and S. A. Rosenberg, Eds.), Lippincott: Philadelphia, pp. 1226-1263 (1993).
4. Chambers, J. T. Borderline ovarian tumors: A review of treatment, Yale J. Biol. Med. 62(4), 351-365 (1989).
5. Gallion, H. H., and Bast, R. C., Jr. National Cancer Institute conference on investigational strategies for detection and intervention in early ovarian cancer, Cancer Res. 53, 3839-3842 (1993).
6. Szamborski, J., et al. Case control study of high-risk factors in ovarian cancer, Gynecol. Oncol. 11, 8-16 (1981).
7. Parazzini, F., et al. Risk factors for epithelial ovarian tumours of border-line malignancy, Int. J. Epidemiol. 20(4), 871-877 (1991).
8. Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives, Int. J. Epidemiol. 18, 538-545 (1989).
9. Willett, W. C., et al. Oral contraceptives and risk of ovarian cancer, Cancer 48, 1684-1687 (1981).
10. Goldberg, G. L., and Runowicz, C. D. Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation - Is there a link? Am. J. Obstet. Gynecol. 166, 853-854 (1992).
11. Nijman, H. W., et al. Borderline malignancy of the ovary and controlled hyperstimulation, a report of 2 cases, Eur. J. Cancer 28A(12), 1971-1973 (1992).
12. Rossing, M. A., et al. Ovarian tumors in a cohort of infertile women, N. Engl. J. Med. 331, 771-776 (1994).
13. Henderson, W. J., et al. Talc and carcinoma of the ovary and cervix, J. Obstet. Gynaecol. Br. Commonw. 78, 266-272 (1971).
14. Longo, D. L., and Young, R. C. Cosmetic talc and ovarian cancer, Lancet 2, 349-351 (1979).
15. Cramer, D. W., et al. Ovarian cancer and talc: A case-control study, Cancer 50, 372-376 (1982).
16. Massad, L. S. J., et al. Epithelial ovarian tumors of low malignant potential, Obstet. Gynecol. 78(6), 1027-1032 (1991).
17. Segal, G. H., and Hart, W. R. Ovarian serous tumors of low malignant potential (serous borderline tumors): The relationship of exophytic sur-face tumor to peritoneal "implants," Am. J. Surg. Pathol. 16(6), 577-583 (1992).
18. Cannistra, S. A., et al. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H, Cancer Res. 53, 3830-3838 (1993).
19. de Nictolis, M., et al. Serous borderline tumors of the ovary: A clinicopatholgic, immunohistochemical, and quantitative study of 44 cases, Cancer 70, 152-160 (1992).
20. Robey, S. S., and Silva, E. G. Epithelial hyperplasia of the fallopian tube: Its association with serous borderline tumors of the ovary, Int. J. of Gynecol. Pathol. 8, 214-220 (1989).
21. Baird, D. B., and Reddick, R. L. Extraovarian mucinous metaplasia in a patient with bilateral mucinous borderline ovarian tumors: A case report, Int. J. of Gynecol. Pathol. 10, 96-103 (1991).
22. Dallenbach-Hellweg, G. Epithelial hyperplasia of the fallopian tube, Int. J. Gynecol. Pathol. 9, 382-383 (1990).
23. Komitowski, D., et al. Quantitative nuclear morphology in the diagnosis of ovarian tumors of low malignant potential (borderline), Cancer 64, 905-910 (1989).
24. Khattech, A., et al. Nucleolar organizer regions in ovarian tumors: Discrimination between carcinoma and borderline tumor, Int. J. Gynecol. Pathol. 11, 11-14 (1992).
25. Tavassoli, F. A. Serous tumor of low malignant potential with early stromal invasion (serous LMP with microinvasion), Mod. Pathol. 1, 407-414 (1988).
26. Shiraki, M., et al. Ovarian serous borderline epithelial tumors with multiple retroperitoneal nodal involvement: Metastasis or malignant transformation of epithelial glandular inclusions? Gynecol. Oncol. 46, 255-258 (1992).
27. Leake, J. F., et al. Retroperitoneal lymphatic involvement with epithelial ovarian tumors of low malignant potential, Gynecol. Oncol. 42, 124-130 (1991).
28. Bell, D. A., Weinstock, M. A., and Scully, R. E. Peritoneal implants of ovarian serous borderline tumors. Histologic features and prognosis, Cancer 62, 2212-2222 (1988).
29. Fort, M. G., et al. Evidence for the efficacy of adjuvant therapy in epithelial ovarian tumors of low malignant potential, Gynecol. Oncol. 32(3), 269-272 (1989).
30. Nakashima, N., et al. Ovarian epithelial tumors of borderline malignancy in Japan, Gynecol. Oncol. 38, 90-98 (1990).
31. Vaccarello, L., et al. Tumor-infiltrating lymphocytes from ovarian tumors of low malignant potential, Int. J. Gynecol. Pathol. 12, 41-50 (1993).
32. Neunteufel, W., et al. Ovarian tumors of low malignant potential (borderline tumors): Immune morphology and current status, Anticancer Res. 9, 993-997 (1989).
33. Harlow, B. L., Weiss, N. S., and Holmes, E. H. Plasma α-I-fucosidase activity and the risk of borderline epithelial ovarian tumors, Cancer Res. 50, 4702-4703 (1990).
34. Kaern, J., et al. Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary, Gynecol. Oncol. 38, 452-457 (1990).
35. Kuhn, W., et al. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors, Gynecol. Oncol. 33, 360-367 (1989).
36. Vergote, I., Kaern, J., and Trope, C. Adjuvant treatment of stage I ovarian cancer: How can we prevent over-treatment? Proc. Annu. Meet. Am. Soc. Clin. Oncol. 11, A715 (1992).
37. Padberg, B. C., et al. DNA-cytophotometry and immunocytochemistry in ovarian tumours of borderline malignancy and related peritoneal lesions, Virchows Archiv. A Pathol. Anat. Histopathol. 421(6), 497-503 (1992).
38. Friedlander, M. L., et al. Prediction of long term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer, J. Clin. Oncol. 6, 282-290 (1988).
39. Dodson, M. K., et al. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas, Cancer Res. 53, 4456-4460 (1993).
40. Marks, J. R., et al. Overexpression and mutation of p53 in epithelial ovarian cancer, Cancer Res. 51, 2979-2984 (1991).
41. Dodson, M. K., et al. Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus, Cancer Res. 54, 610-613 (1994).
42. Kim, T. M., et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression, Cancer Res. 54, 605-609 (1994).
43. Zheng, J. P., et al. Distinction of low grade from high grade human ovarian cancer on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and Her-2/neu gene amplification, Cancer Res. 51, 4045-4051 (1991).
44. Zheng, J., et al. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular character-istics of high-grade carcinomas, Cancer Res. 53, 4138-4142 (1993).
45. Mok, S. C., et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy, Cancer Res. 53, 1489-1492 (1993).
46. Ichikawa, Y., et al. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors, Cancer Res. 54, 33-35 (1994).
47. Enomoto, T., et al. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary, Am. J. Pathol. 139, 777-785 (1991).
48. Slamon, D. J., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science 244, 707-712 (1989).
49. Kacinski, B. M., et al. NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms, Gynecol. Oncol. 44, 245-253 (1992).
50. Henriksen, R., et al. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms, Cancer Res. 53, 4550-4554 (1993).
51. Bauer, E. A., et al. Stimulation of in vitro human collagenase expression by platelet-derived growth factor, Proc. Natl. Acad. Sci. USA 82, 4132-4136 (1985).
52. Miki, Y., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science 266, 66-71 (1994).
53. Struewing, J. P., et al. Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer, Am. J. Hum. Genet. 57, 1-7 (1995).
54. Friedman, L. S., et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families, Nat. Genet. 8, 399-404 (1994).
55. Futreal, P. A., et al. BRCA1 mutations in primary breast and ovarian carcinomas, Science 266, 120-122 (1994).
56. Hosking, L., et al. A somatic BRCA1 mutation in an ovarian tumour, Nat. Genet. 9, 343-344 (1995).
57. Merajver, S. D. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours, Nat. Genet. 9, 439-443 (1995).
58. Hanigan, M. H., et al. Human ovarian tumors express gamma-glutamyl transpeptidase, Cancer Res. 54, 286-290 (1994).
59. Olson, T. A., et al. Vascular permeability factor gene expression in normal and neoplastic human ovaries, Cancer Res. 54, 276-280 (1994).
60. Dabholkar, M., et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients, J. Natl. Cancer Inst. 84, 1512-1517 (1992).
61. Dabholkar, M., et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy, J. Clin. Invest. 94, 703-708 (1994).
62. Conter, C. M., et al. Telomerase activity in human ovarian carcinoma, Proc. Natl. Acad. Sci. USA 91, 2900-2904 (1994).
63. McLellan, R., et al. Investigation of ovarian neoplasia of low malignant potential for human papillomavirus, Gynecol. Oncol. 38, 383-385 (1990).
64. Volgestein, B., and Kinzler, K. W. The multistep nature of cancer, Trends Genet., 138-141 (1993).